搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
centerforbiosimilars
1 天
The Top 5 Biosimilar Articles for the Week of September 16
Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...
centerforbiosimilars
4 天
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and ...
centerforbiosimilars
4 天
Christina Corridon, MPH, MBA
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD ...
centerforbiosimilars
4 天
FDA Approves Pavblu for Retinal Conditions
Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...
centerforbiosimilars
4 天
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of ...
centerforbiosimilars
6 天
STADA Credits Biosimilar Expansion for Profitable First Half of 2024
German biosimilar manufacturer STADA Arzneimittel reported a 9% revenue increase in the first half of 2024, with over €2 ...
centerforbiosimilars
7 天
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈